QNCX
Quince Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$29.48
+9.14%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$27.21
From 52W high−96.65%
Volume48829.00
Market cap$29.98M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$27.21
From 52W high
−96.65%
Volume
48829.00
Market cap
$29.98M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
P/E (TTM)
—
RSI (14)
51.6
MomentumView details →
1D Return
+9.14%
YTD Return
−95.54%
SummaryUpdated Jun 1, 2026
Quince Therapeutics, Inc. (NASDAQ:QNCX) is a biopharmaceutical company founded in 2012 and headquartered in South San Francisco, California. Originally incorporated as Cortexyme, Inc., the company rebranded to Quince Therapeutics in August 2022 following a strategic pivot in its research focus. The company went public in May 2019 and currently operates as a clinical-stage biotechnology firm specializing in precision therapeutics for debilitating and rare diseases, with a particular emphasis on bone-targeting drug delivery technologies.
Similar companies
Latest newsMore news →
Quince Therapeutics, Inc. completed the sale of its subsidiary Quince Therapeutics SpA, certain AIDE-technology intellectual property, and all AIDE and eDSP machines and systems to Ayma Therapeutics, Inc. for $450,000 in cash.6d agoDelveInsight published a market research report on the sarcoidosis treatment market, forecasting growth through 2036 and highlighting emerging therapies.12d agoCharles Ryan departed as President of Quince Therapeutics, Inc., effective September 8, 2026, and is eligible for severance benefits under his Executive Change in Control and Severance Agreement dated September 1, 2023.25d ago